Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Feb. 16 — Drug companies that develop a Zika virus vaccine could be eligible for a tax credit under a slate of bills introduced in the House Feb. 12 designed to reduce the spread of the mosquito-borne virus.
Rep. Curt Clawson (R-Fla.) said he introduced a three-part legislative package on Zika to combat a virus that has spread to more than 30 nations throughout the Americas as a multipronged approach to prevent Zika infection, to ensure that the disease doesn't become prevalent in the U.S. and to ensure that localities are prepared to deal with any instances of outbreak as they arise. The White House has requested $1.8 billion in emergency funds to fight the disease .
“The explosive spread of this mosquito-borne virus, exacerbated by a lack of vaccines and reliable diagnostic tests, must be curbed utilizing every tool at our disposal in a coordinated international response,” Clawson said in a Feb. 12 statement. “The Zika virus is sneaking up on us and we’re not paying enough attention. If we deal with it prior to an outbreak we will be much better off.”
The lawmaker said that his district in southwest Florida’s Gulf Coast is “highly susceptible” to an outbreak, especially because the mosquito that is the main carrier of the virus is widely found in Florida.
The three bills introduced by Clawson are:
Similar legislation to repurpose the emergency funding provided last year for Ebola already have been introduced by other members in the House (H.R. 4446) and the Senate (S. 2518) . While he acknowledged that “the funds could still be used for Ebola as necessary,” he said in a Feb. 12 statement that “this bill would expand the availability of the funds to also be used in the fight against Zika.” Key public health leaders indicated in recent testimony before the Senate that re-appropriating Ebola dollars for Zika won't work because they haven't finished their work in Ebola and all that money has been obligated .
Both H.R. 4561 and H.R. 4562 have been referred to the House Energy and Commerce Committee; H.R. 4563, which would provide the tax credit, has been referred to the House Ways and Means Committee.
To contact the reporter on this story: Jeannie Baumann in Washington at email@example.com
To contact the editor responsible for this story: Nancy Simmons at firstname.lastname@example.org
The text of the H.R 4561 is available at https://www.congress.gov/bill/114th-congress/house-bill/4561/text.
The text of the H.R 4562 is at https://www.congress.gov/bill/114th-congress/house-bill/4562/.
The text of the H.R 4563 is at https://www.congress.gov/bill/114th-congress/house-bill/4563/text.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)